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RESUMO: A glicose é um nutriente essencial para o organismo humano, sendo a principal fonte de energia para muitas células que 
dependem da circulação sangüínea, afim de suprir suas necessidades. Dessa forma, a presente revisão literária enfatizou a glicogenose 
tipo I, uma doença caracterizada pela deficiência da enzima glicose-6-fosfatase, responsável por catalisar a hidrólise de glicose-6-fosfato 
á glicose e fosfato, nas etapas finais tanto da gliconeogênese como da glicogenólise. Os estudos recentemente consentiram da necessidade 
do uso freqüente de altas taxas de amido nas refeições diárias, além de infusões intra-gástricas noturnas de líquidos contendo polímeros de 
glicose. Além disso, o presente trabalho também alerta as pessoas sobre o meticuloso cuidado sobre os pacientes portadores desta doença, 
afim de proporcionar uma melhor qualidade de vida para os mesmos, bem como evitar complicações e subseqüentes prognósticos.
PALAVRAS-CHAVE: glicogenose tipo I; glicólise; gliconeogênese.
A COMPREHENSIVE REVIEW ON GLYCOGENOSIS TYPE I
ABSTRACT: Glucose is an essential nutrient for human organism, being the main source of energy for a lot of cells which depend on 
blood stream in order to supply their needs. Therefore, this literature review emphasized glycogenosis type I, a disease characterized by 
deficiency of the enzyme glucose-6-phospatase, responsible to catalyze the hydrolysis of glucose-6-phosphate into glucose and phosphate, 
in the final steps not only neoglucogenesis but also glycogenolysis. Recent studies revealed the need for recurrent use of high rates of starch 
in diary meals, beyond nocturnal intra-gastric infusions of liquids containing glucose polymers. Moreover, this study also alerts people 
with respect to the meticulous care to those patients in order to provide them a better life style and prevent complications and subsequent 
prognostics.
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Introdução
The glucose is an essential nutrient for human 
organism, being the major energy source for a lot of 
cells that depend on blood steam, in order to supply 
their needs (NORDLIE; FOSTER, 1999). Therefo-
re, the D-glucose is considered as main fuel due to its 
wealth in potential energy provided (NELSON; COX, 
2002). 
The degradation of glycogen, the neoglucoge-
nesis and a diet compose primary sources, which allow 
an obtaining of glucose from the blood. Nevertheless, 
the hepatic glycogenolysis, in absence of a diet source 
of glucose, is a mechanism that recomposes glucose ra-
tes in a fast way (CHAMPE; HARVEY, 1996). 
On the other hand, muscle glycogenolysis is in-
tense when activities are done. Thus, the liver represents 
an important function in the regulation of glucose’s 
stock and storage, from pathways of, glycogenolysis, 
and finally, neoglucogenesis (NORDLIE; FOSTER, 
1999).
During postprandial period, endogenous glu-
cose production is ceased and blood glucose level in-
creases. Thus, exogenous glucose could be metabolized 
to pyruvate or stored as glycogen in liver and skele-
tal muscle. However, under aerobic conditions, pyru-
vate might follow two different pathwaths. Firstly, it 
can be converted to acetyl coenzyme A (acetyl-CoA) 
that goes into the citric acid cycle, and which products 
are water, carbon dioxide and adenosine triphosphate 
(ATP). Secondly, it could be used for the synthesis of 
fatty acids. In opposition, pyruvate is converted to lac-
tate under anaerobic conditions, and then, consists on 
an important alternative fuel during hypoglycemia epi-
sodes. Therefore, different hormones, such as insulin, 
glucagon, cortisol and others, regulate the relationship 
of glycolysis, gluneogenesis and glycogen synthesis 
(figure 1) (NELSON; COX; 2002, ROACH, 2002).
Glycogen storage diseases (GSD) consist on 
pathological conditions of inherited metabolic errors 
that result in abnormalities of glycogen concentration 
and/or structure in any type of organ tissue (REIS et al. 
1999).
Glycogen storage disease type 1 (Von Gierke 
disease; glucose-6-phosphatase deficiency, hepatore-
nal glycogenosis) is defined as an autosomal recessive 
disorder, characterized by deficiency of the glucose-6-
phosphate (G6Pase) activity (CORI; CORI, 1952).
The disease was first reported by Edgar Von 
Gierke, in 1929, when evidenced an enlargement in 
one patient due to a solid increasing of the liver (hepa-
tomegaly) and pronounced hypoglycemia between the 
meals. 
Although it is hard to estimate accurately, its in-
cidence is 1:100,000 to 1:400,000 births in the general 
Caucasian population, with types 1b and 1c being much 
less frequent than type 1a. However, type 1a prevalen-
ce is 1:20,000 in Ashkenazi Jews population, probably 
due to R83C mutation is the only one prevalent in the 
Ashkenazi Jewish population (EKSTEIN et al., 2004).
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Figure 1: Glycogen synthesis and degradation simplified pathway.
The most important criteria adopted for this 
diagnostic were hepatomegaly, hypoglicemia and hy-
perlacticidemia (FROISSART; MAIRE, 2002).  Be-
yond that, the blood glucose level does not rise, even 
with administration of epinephrine or glucagon. Thus, 
it can be reported clinical conditions of convulsion du-
ring periods of low glucose level (BERG et al., 2004).
Therefore, the present work had as objective to 
review some aspects of the glycogen storage disease 
related to the etiology, clinical symptoms, diagnosis, 
and treatment, in order to disseminate and improve the 
knowledge about this disorder, especially among health 
care professionals.
ETIOLOGY
The glycogen storage disease (GSD) type 1 is 
caused by a deficiency of the enzyme glucose-6-phos-
patase (G6Pase), which affects glycogenolysis and glu-
coneogenesis (SHIEH et al., 2002).
G6Pase is mainly found in the liver and the 
kidneys, and plays an important role to provide glucose 
during starvation period. Besides that, it functions as 
a multicomponent system and it is associated with the 
luminal surface of endoplasmic reticulum (ER), where 
this enzyme has an active site (VAN SCHAFTINGEN; 
GERIN; 2002).
Additionally, G6Pase has at least three trans-
porter proteins in addition to the catalytic subunit and 
calcium linked to regulatory protein (BURCHELL; 
WADDELL, 1993; SHIN, 1993). These transporter 
protein functions as follow: T1 carries G6P through 
endoplasmic reticulum membrane (ER); T2 transports 
pyrophosphate to ER lumen and in contrary direction 
the phosphate liberated by G6P degradation reaction; 
and finally T3 that leads glucose, free by G6P hydro-
lysis, out of the ER (WADDELL; BURCHELL, 1993; 
WADDELL; HUME; BURCHELL, 1989). 
Cori and Cori (1952) demonstrated that an en-
zymatic deficit of GSD I affects mainly certain organs, 
such as liver and kidneys, and in a less aggressive way 
bowel and pancreas (FROISSART; MAIRE, 2002). 
Senior and Loridan (1968) found out that in 
some patients in vitro G6Pase activity was normal des-
pite that glucose was not liberated from G6Pase in vivo. 
Thus, it was characterized as GSD type 1b. 
In order to detail and explain this fact, Arion 
et al. (1975) elaborated a hypothesis that the hydroly-
sis of G6P requires a lot of membrane proteins. Thus, 
amongst them, the catalytic unity (G6Pase) skilled of 
hydrolyzing several phosphate esters (G6P, mannose-
6-phosphate, carbamylphosphate and pyrophosphate); 
and G6P- specific bidirectional translocase (G6PT1), 
which should guarantee its entrance on the lumen of 
endoplasmic reticulum, where occurs the linkage and 
activation of G6Pase. Recently, the G6PT encoding 
gene has been identified on chromosome 11q23, and 
consequently sequenced (ANNABI et al., 1998; IHA-
RA; KUROMARU; HARA,1998). 
Hence, glucose-6-phosphate deficiency was 
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assigned as glycogenosis type 1a, whereas the deficit 
of G6PT1 causes glycogenosis type 1b (FROISSART; 
MAIRE, 2002).
In 1983, one patient with deficit on the enzy-
me specific bidirectional translocase for phosphate 
(G6PT2) was described by Nordlie et al. The G6PT2 
allows phosphate to leave the endoplasmic reticulum, 
resulting, then, in a hydrolysis of G6P out of it. No-
netheless, an existence of glycogenosis 1c was put in 
doubt due to mutations on the gene responsible for 
codifying G6PT1 (VEIGA-DA-CUNHA et al., 1998). 
Unlike, the existence of glycogenosis type 1d, attri-
buted to a deficit of translocase (G6PT3) that allows 
glucose’s exit to endoplasmic reticulum has not been 
proved (FROISSART; MAIRE, 2002). 
Liver microsomal transport of phosphate and 
glucose is respectively deficient in GDS 1c and 1d. 
Through molecular analyses, patients that apparently 
present type 1c and 1d confirmed by biochemical and 
clinical diagnosis usually do not present different mu-
tations from those who have GSD 1b (FENSKE et al., 
1998; VEIGA-DA-CUNHA et al., 1999). Thus, the oc-
currence of very similar mutations in GSD type 1b and 
1c could suggest either that there is one transporter for 
both pyruvate and glucose-6-phosphate (G6P) or that 
the biochemical assays used to differentiate pyruvate 
transporter defect from G6P transport defects are not 
reliable.  
Nowadays, it is taken into consideration 2 sub-
types of glycogen storage disease type 1, and each one 
depends particularly on the abnormality in the G6Pase. 
The defect observed on the catalytic subunit of the sys-
tem, which is located inside of ER causes GSD type 1a. 
The G6PT transporter defect results in GSD type 1b. 
Besides that, the presence of 1c and1d types have been 
also postulated. Since, there were reported patients with 
kinetic and enzymatic pattern indicative of GSD 1c 
with absence of mutations in both G6Pase and G6PT, it 
raises the question related to the existence of a separate 
locus for GSD 1c (MELIS et al., 2004). Therefore, Na/
phosphate co-transporter 4, which is expressed in the 
liver and kidney, is a possible candidate for GSD 1c.
CLINICAL SYMPTOMS
In the first weeks of life, the disease can mani-
fested from a perception of hepatomegaly. In addition, 
main clinical manifestations consist on hepatic adeno-
mas, anemia, osteopenia and/or fractures, and ovarian 
cysts (FROISSART; MAIRE, 2002).  
 The hypoglycemia could result in 
convulsion condition and hyperlacticacidemia, conse-
quently, causes severe increase of metabolic acidosis, 
factor that justifies the initial gravity of the disease 
(FROISSART; MAIRE, 2002). 
The crisis of hypoglicemia could also provide 
increase of hormones regulation, as cortisone. On the 
other hand, tolerance to fast period is very limited, once 
the patients that present this problem hardly will keep 
the homeostasis of serum glucose (TALENTE et al., 
1994). 
Patients with GSD 1a usually present initial 
symptoms because of hypoglycemia, right after birth, 
and episodes do not respond to glucagon administra-
tion. It is commonly observed irritability, tremors, ap-
nea, hyperventilation, cyanosis, convulsions, paleness, 
sweating, cerebral edema/dysfunction, coma and death, 
especially in the morning or before feedings. Older in-
fants might show doll-like facial appearance, tremors, 
overwhelming hunger, growth retardation, difficult 
arousal from sleep. Besides that, it is noticed an impai-
red platelet function that provides a tendency to nose 
bleeding, particularly in those with insufficient meta-
bolic control (RAKE et al., 2002a, 2002b). In adults 
hostage of type 1a, the glucose can reach level of 
2.8mmol/L (50mg/dL) after nocturnal fast (TALENTE 
et al., 1994).
GSD 1a patients, as well as those with 1b, may 
suffer from intermittent diarrhea, which seems to wor-
sen with age, and its cause remains unknown (VISSER 
et al., 2002). A hypothesis implies as  main cause the 
mucosal barrier integrity loss due to disturbed intestinal 
function, which occurs as a result of inflammation, and 
loss of neutrophil function as well, which often occurs 
in patients with GSD lb.
Most noticeable laboratory abnormalities, in 
addition to hypoglycemia, are lactic acidosis, hyperlipi-
demia (in particular to hypertriglyceridemia) and hype-
ruricemia (SALTIK et al., 2000; RAKE et al., 2002a).
Lactic acid, usually produced during anaerobic 
process in the muscles and erythrocytes, is removed 
and metabolized by the liver through citric acid and 
pyruvate cycles, deviating to fatty acid synthesis or glu-
coneogenesis (NELSON; COX, 2002).  Thus, since the 
brain is capable of metabolizing lactate, acting then, as 
protector for central nervous system, and consequently, 
mental disorders are not common to this situation (TA-
LANTE et al., 1994).
On the other hand, hyperlipidemia consists on 
increasing of glycolytic products as NADP, NADH, 
phosphate, glycerol-3-phosphate and co-enzyme A, 
which are essential for fatty acid and cholesterol syn-
theses.  The accumulation of lipids and hyperlipidemia 
are factors caused by a great influx of fat acid into the 
liver, then, being them responsible for the low rate of 
insulin and increasing on the concentration of gluca-
gon and cortisone (CALÇADO, 1996; GHISHAN; 
BALLWE, 1994; TALENTE et al., 1994). Also, it is 
observed on histopatological findings of liver swollen 
hepatocytes, steatosis, nuclear hyperglycogenation and 
mosaic pattern with pale-staining. The swollen and 
rounded face is consequence due to deposit of fat, what 
may cause appearance of xanthomas, as well as protru-
ding abdomen in contrast with members that are thin 
(FROISSART; MAIRE, 2002). Other signs constantly 
present constitute late puberty and low stature charac-
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terized with an osteopenia (LEE et al., 1995). Beyond 
that, hyperlipidemia may also cause cholelithiasis 
(gallstones).  
The dyslipidemia demonstrated as a contribu-
tion factor for increasing the risk of pancreatitis (KIKU-
CHI et al., 1991), hence, not much as for atherosclero-
sis or other cardiovascular complications (TRIOCHE 
et al., 2000).
With ageing, the prevalence of renal invol-
vement increases (CHEN et al., 1988). Even though 
they still symmetrical, kidneys suffer an enlargement 
(BERG et al., 2004). The renal complications are detec-
ted through initial process of glomerular hyperfiltration 
before development of proteinuria, with advance of re-
nal insufficiency. The hypercalciuria, which is also con-
sidered common, and hypocitraturia cause nephrocalci-
nosis and/or urolithiasis (LIN et al., 2005). Therefore, 
hyperuricemia must be treated in order to prevent com-
plication of renal system (REITSMA-BIERENS, 1993; 
RESTAINO et al., 1993) and hypocitraturia (WEINS-
TEIN et al., 2001). In some cases, kidney transplan-
tation may be necessary in GSD type 1b patients that 
develop terminal kidney disease, which is considered 
rare (MARTIN, et al., 2006).
Growth retardation in children is a remarkable 
finding in most patients (SMIT, 1993; SALTIK et al., 
2000), as well as short stature is common among adult 
patients (TALENTE et al., 1994).
Additionally, without effective treatment, long-
term complications occur, namely hepatic adenomas, 
gout, anemia, osteopenia and/or fractures, increase of 
alkaline phosphatase and gamma-glutamyltransferase, 
gout. Osteoporosis may be related to poor nutrition, the 
effects of lactic acid and hypogonadism (CABRERA-
ABREU et al., 2004).
In 1969, Zanzeneh et al. reported for the first 
time hepatic carcinoma in patients with GSD, obser-
ving a switch from hepatic adenoma to carcinoma du-
ring a period of 18 months.
According to studies, hepatic adenoma may 
develop at any age, and might undergo malignant trans-
formation within a period as long as 28 years (FRAU-
MENI  et al., 1969; ZANGENEH et al., 1969; MILLER 
et al., 1978; LEE et al., 1994; FRANCO et al., 2005). 
Normally, hepatic adenoma is prevalent in a ratio of 2:1 
in males, whereas adenomas of other types of origin 
prevails in females (BIANCHI, 1993). 
Levels of alpha fetoprotein may be altered, high 
without malignant transformation or even normal under 
malignant alteration, because of that is recommended to 
run abdominal ultrasonography and also to check car-
cinoembryonic antigen concentration every three mon-
ths, once patient develop hepatic lesions (FRANCO et 
al., 2005). However, when lesions are either larger or 
growing large, or also poorly defined, it is advised to do 
clinical exams as abdominal tomography and/or mag-
netic resonance imaging. 
Prevalence hepatic adenoma ranges from 22% 
to 75% usually during or after puberty, but it can also be 
diagnosed in children younger than a year of age. The 
pathogenesis still unknown, however, a high glucagon/
insulin ratio, glycogen accumulation in cells and pro-
tooncogene/oncogene activation or mutations has been 
proposed (BIANCHI, 1993). 
A peculiar characteristic of GSD 1b is the obser-
vation of inflammatory bowel disease (Crohn’s disease) 
like colitis (ROE et al., 1986; SALTIK-TEMIZEL et al., 
2005). However, the severity of GSD is not correlated 
with the intestinal symptoms; fever, diarrhea, perioral 
and anal ulcers are some of the accompanying findings 
and clinical features.  Besides that, all have absolute 
neutrophil count less than 1,000cells/mL.
Besides that, severe infectious complications 
may occur because of netropenia and functional de-
fects of PMNs and monocytes. Otitis, gingivitis, and 
boils might be common in young children with GSD 1b 
(VISSER et al., 2000).
The literature evidenced some cases of preg-
nancy, but due to the aggravating renal risk turns the 
woman more susceptible to hemorrhages, therefore, to 
keep the metabolic balance of the fetus is needed one 
restrict particular monitoring for it (RYAN et al., 1994). 
A recent study carried out by Martens et al. (2008) with 
15 pregnant women with glycogen storage disease type 
1 investigated the following characteristics: carbo-
hydrate requirement, triglyceride and uric acid levels, 
liver ultrasonography, creatinine clearance. The authors 
observed a significant increase of carbohydrate requi-
rement, whereas most patients presented an acceptable 
level of triglyceride and uric acid. It was not observed 
increase in matters of size and/or number of adenomas. 
Even though there are some GSD type 1 related risks, 
successful pregnancies are possible in patients who are 
carries of this disorder.
DIAGNOSIS 
During the 70s, patients with GSD were admit-
ted frequently in hospitals due to hypoglycemia, fever 
and acidosis. Mortality ratio was high, and permanent 
neurological damage could not be avoided. The pa-
tients who were able to survive through this situation, 
commonly presented a late growth and psychomotor 
development (MOSES, 1990; SMIT, 1993).
The deficiency on the enzyme glucose-6-
phosphate could be diagnosed through clinical me-
thods, among them the basic work-up, the indirect tests, 
a studying of the system G6Pase by hepatic biopsy, a 
molecular studying, genetic counseling and prenatal 
exams. 
Normally, GSD 1a is suspected on the basis of 
a set of clinical and biochemical features. Therefore, a 
definitive diagnosis should confirm by a liver biopsy 
and enzyme assay, or by mutation analysis. As a result, 
it becomes important and necessary the development of 
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a rapid and minimally invasive diagnostic method.
The basic work-up consists in analyses that re-
veal conditions of hypoglicemia, hyperlacticacidemia, 
hypercholesterolemia, hypertriglyceridemia and hype-
ruricemia (MAIRE et al., 1991).
Other procedures to verify the presence of this 
disorder, would include glucagon and epinephrine tests 
that maintain glucose level, but increase of lactic acid 
plasma level. Plasma lactic acid is also raised when 
galactose and fructose (1.75g/Kg) are orally  adminis-
trated, without changing glucose level. Contrary, when 
glucose intolerance test is carried out, lactic acid level 
progressively lowers over several hours after adminis-
tration (STOJANOV; KARADAGLIC, 2008).
Nonetheless, indirect tests are correlated to the 
lack of glycemic answer and aggravating of hyperlacti-
cacidemia, when patient, in period of fast or ingestion 
of high carbohydrate meal, receives a dosage of gluca-
gon equivalent to 1mg/m2 of corporal surface.
Nevertheless, the studying of G6Pase system 
requires a natural hepatic sample, not frozen, of the 
liver, which is homogenized and submitted to prior 
determined examinations. When hydrolytic activity is 
defective, GSD Ia is considered given the importance 
to microsomal membranes, since in GSD Ib those still 
intact.
In Caucasians with GSD 1a, R83C and Q347X 
are the most prevalent mutations, whereas 130X and 
R83 C in Hispanics, and only R83H is observed in Chi-
nese (LEI et al., 1995). Therefore, DNA-based analysis 
could accurately, rapidly, and noninvasively detect the 
majority of mutations in GSD type la, allowing prenatal 
diagnosis among at-risk patients, serving as screening 
and counseling for clinical patients suspected of having 
this disease, as well.
Even though, some of these genetic molecular 
tests were already proved and accepted by the scientific 
community, it still remains some doubts and hypothe-
sis, which were not confirmed about this subject.
On the other hand, genetic counseling is very 
important because allow an identification of hetero-
zygote individuals in the family. Consequently, it is 
possible to warn the parents of the probable birth of 
child with this deficiency, as well as the caring proce-
dures that must be done, so then, guarantee welfare and 
also his or her social living at the community. 
TREATMENT 
The current treatment for GSD I consists of die-
tary therapy, with frequent use of high rates of starch in 
diary meals, including nasogastric infusion of glucose 
(liquid containing glucose polymers) (FOLK; GREE-
NE, 1984).  The therapeutic diet has the purpose to help 
the maintenance of normoglycemia, correcting then, 
metabolic abnormalities and improving the function of 
the proximal renal tube (CHEN, 1991). In contrast, the 
efficacy of dietary treatment is usually compromised 
by the poor compliance. Further, it should be restricted 
the intake of fructose and galactose, since it has been 
demonstrated that they cannot be converted to glucose 
but that they do increase lactate production (STOJA-
NOV; KARADAGLIC, 2008).
Additionally, administration of granylocyte co-
lony-stimulating factor (G-CSF) may restore myeloid 
functions. A combination of G-CSF and dietary thera-
pies significantly relieves the metabolic and myeloid 
abnormalities of GSD 1b patients and their prognosis 
is greatly improved (SCHROTEN et al., 1991; ROE 
et al., 1992). Nonetheless, long-terms complications, 
such as kidney disease in the form of calculi and pro-
gressive terminal renal disease, inflammatory bowel 
disease, hepatic adenomas, splenomegaly, may appear 
significantly in adults because of lack of treatment for 
the underlying pathological process.
Even though, no specific drug treatment is re-
commended for GSD, when an infection is detected, 
should be given antibiotics. The combination of anti-
biotics and granulocyte-macrophage colony-stimula-
ting factors is recommended for GSD 1b patients that 
reveal severe infection and/or chronic inflammatory 
bowel disease (STOJANOV; KARADAGLIC, 2008). 
On the other hand, allopurinol (10mg/Kg per 
day, 3 doses) should be administrated if hyperuricemia 
is present. Bicarbonate (1-2mmol/Kg per day in 4 do-
ses) or potassium citrate (5-10mEq every 8-12h) should 
be prescribed when acidosis is noticeable (RAKE, et 
al., 2002). Besides that, angiotensin converting enzy-
me (ACE) are useful for reducing microalbuminuria, 
and aside of their antihypertensive effects, they also 
renoprotective and decrease albuminuria (OZEN et al., 
2000; GIANNI et al., 2002). Citrate therapy can pre-
vent nephrocalcinosis and renal calculi (STOJANOV; 
KARADAGLIC, 2008).  
Lipid-lowering drugs (such as 3-hydroxy-3-
methylglutaryl coenzyme A [HMG-CoA] reductase 
inhibitors, fibric acid derivatives)  could be used in 
purpose to reduce hyperlipidemias. Beyond that, if cho-
lesterol levels are persistently elevated (>8-10mmol/L) 
in adults patients, statins (HMG-CoA reductase inhi-
bitors of cholesterol biosynthesis in the liver), should 
be given. Moreover, ezetimine, a new inhibitor of cho-
lesterol absorption is capable to reduce low-density li-
poprotein (LDL) cholesterol levels and has small tri-
glyceride-lowering effects as well (RAKE et al., 2002; 
STOJANOV; KARADAGLIC, 2008).
Gene therapy is an encouraging care but is not 
available yet. Studying carried out by Yiu et al. (2007) 
has demonstrated that after adenoviral vectors infusion, 
containing G6PT into G6PT knock-out mice, levels of 
G6PT mRNA expression in the liver, bone marrow and 
spleen were restored, being also myeloid abnormalities 
corrected. Therefore, the effective use of gene therapy 
in order to adjust metabolic imbalances and myeloid 
dysfunctions in GSD mice may hold a promising hu-
man gene therapy. 
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Once the patient with this disease searches for 
a better life style in order to increase her or his sur-
vival index, turns out to be necessary the attention of 
nutritionists, not only for adults but also for children, 
with the purpose to make familiar all the recommended 
treatment methods (FOLK; GREENE, 1984). Hence, it 
must be carried out an evaluation to verify the progress 
of renal diseases (CHEN, 1991). 
Therefore, the care in a meticulous treatment 
presents great impact on in the life quality of the pa-
tient, prevention of complications and subsequent 
prognostics (MOSES, 2002). 
FINAL CONSIDERATIONS
In summary, more detailed studying might be 
required, since until now it remains unsolved the ques-
tion about the existence of glycogenosis type Ic, as well 
as the nature of possible interactions between the whole 
G6Pase system (FROISSART; MAIRE, 2002). Beyond 
that, it is also very important to look forward the pa-
tient quality life, as well as her or his integration to the 
society. Therefore, the counseling turns out to be a very 
powerful tool on orientating parents and family about 
the disease, in order to provide good development for 
this type individual.
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